What's Happening?
Daewoong Therapeutics has announced that its semaglutide microneedle patch has achieved over 80% relative bioavailability compared to injectable formulations in a pilot human pharmacokinetic study. This marks a significant improvement over existing microneedle patches, which typically report around 30% bioavailability. The study involved 70 healthy adults who received either a semaglutide microneedle patch or a subcutaneous injection, with plasma concentrations measured to compare delivery efficiency. The patch demonstrated therapeutic plasma levels for one week, suggesting potential for once-weekly dosing. This innovation addresses the pain of injections and the low efficiency of oral formulations, positioning Daewoong's microneedle technology as a leader in the global drug-delivery market.
AD
Why It's Important?
The development of Daewoong's microneedle patch represents a potential game changer in the obesity treatment market, where delivery technology is expected to be a decisive factor. The global obesity therapeutics market is projected to grow significantly, and technologies that improve bioavailability and patient convenience are likely to determine future market leaders. Microneedle patches offer a needle-free option that could increase adherence among patients who avoid injections. Additionally, Daewoong's patches remain stable at room temperature, reducing distribution costs and medical waste, aligning with sustainability goals in healthcare.
What's Next?
Daewoong Therapeutics plans to expand its microneedle technology to a wide range of biologics and lead the global platform market. The company is preparing for commercialization through technology licensing, co-development, and out-licensing. The microneedle patch's high bioavailability and therapeutic effect provide a strong foundation for global technology transfer and commercialization. Daewoong aims to broaden collaborative initiatives to the global market, leveraging its patented CLOPAM® microneedle platform technology.
Beyond the Headlines
The microneedle patch's ability to maintain therapeutic plasma levels for a week supports the potential for once-weekly dosing, which could simplify treatment regimens and improve patient adherence. The technology also addresses key limitations of current therapies, such as the pain of injections and low drug delivery efficiency of oral formulations. Daewoong's innovation could lead to a shift in how obesity treatments are administered, potentially reducing healthcare costs and improving patient outcomes.
